Nektar Therapeutics NKTR

US Pharmaceuticals

$70.67 ▼ -1.09% ($-0.78)

🔥 High Short Interest 📅 Earnings This Week

Open $70.84

Prev Close $71.45

Day Range $69.50 – $71.43

52W Range $21.02 – $109.00

Market Cap $2.39B

Beta 1.13

EPS (TTM) $-8.32

📋 Company Profile

Industry	Pharmaceuticals
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	1994-05-03
Shares Out.	33,790,000
Website	nektar.com/ ↗
Phone	13026587581
Employees	63
Revenue	$10.9M
Gross Profit	$10.9M
Net Income	-$44.9M
Free Cash Flow	-$203.9M
Total Assets	$763.3M
Total Liabilities	$187.1M
Equity	$576.2M

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.

Nektar Therapeutics is a publicly traded company under the ticker symbol NKTR on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.